Monte Rosa Therapeutics Announces Milestone Achievement Associated with Second Phase 2 Clinical Study Initiation for VAV1-directed Molecular Glue Degrader MRT-6160 (DDY391)
Globe Newswire•28/10/2026•07:00 ET
0
Key Highlights
- ➤$37.5 million milestone payment follows first patient visit in Phase 2 PsA study
- ➤Novartis initiates second Phase 2 study of MRT-6160 in psoriatic arthritis
- ➤Monte Rosa eligible for up to $2.1 billion in development, regulatory, and sales milestones
- ➤Novartis holds exclusive worldwide rights and funds Phase 2 clinical development
- ➤MRT-6160 achieved greater than 90% VAV1 degradation in Phase 1 T cells
Expert Statements
Markus Warmuth, Chief Executive Officer of Monte Rosa Therapeutics
“This Phase 2 study will assess MRT-6160 in participants with active moderate to severe psoriatic arthritis, a disease with significant unmet need and where there is a strong biologic rationale for targeting with a VAV1-directed MGD.”
Markus Warmuth, Chief Executive Officer of Monte Rosa Therapeutics
“This development milestone demonstrates the strong momentum behind our collaboration with Novartis, and we are pleased to continue to work closely with them as they advance development of MRT-6160.”
Phase 2 study to be conducted in participants with active moderate to severe psoriatic arthritis
Novartis conducting study under global exclusive development and commercialization license agreement with Monte Rosa
Get started
Create a free account to read the full story.